What is the level of liabilities of MaxCyte this year?
MaxCyte has a debt balance of 36.11 M USD this year.
MaxCyte Liabilities 2024
MaxCyte Liabilities
36.11 M USD
Ticker
MXCT
ISIN
US57777K1060
WKN
A2AGVE
In 2024, MaxCyte's total liabilities amounted to 36.11 M USD, a 10.42% difference from the 32.7 M USD total liabilities in the previous year.
MaxCyte Aktienanalyse
What does MaxCyte do?
MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing MaxCyte's Liabilities
MaxCyte's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating MaxCyte's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing MaxCyte's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
MaxCyte's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in MaxCyte’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about MaxCyte Stock
What were the liabilities of MaxCyte compared to the previous year?
The liabilities of MaxCyte have increased by 10.42% increased compared to the previous year.
What are the consequences of high debt for investors of MaxCyte?
High liabilities can pose a risk for investors of MaxCyte, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in MaxCyte?
Low liabilities mean that MaxCyte has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of MaxCyte affect the company?
An increase in liabilities of MaxCyte can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of MaxCyte affect the company?
A decrease in the liabilities of MaxCyte can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of MaxCyte?
Some factors that can influence the liabilities of MaxCyte include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of MaxCyte so important for investors?
The liabilities of MaxCyte are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can MaxCyte take to modify the liabilities?
To change its liabilities, MaxCyte can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does MaxCyte pay?
Over the past 12 months, MaxCyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MaxCyte is expected to pay a dividend of 0 USD.
What is the dividend yield of MaxCyte?
The current dividend yield of MaxCyte is .
When does MaxCyte pay dividends?
MaxCyte pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of MaxCyte?
MaxCyte paid dividends every year for the past 0 years.
What is the dividend of MaxCyte?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is MaxCyte located?
MaxCyte is assigned to the 'Health' sector.
Wann musste ich die Aktien von MaxCyte kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of MaxCyte from 6/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/30/2024.
When did MaxCyte pay the last dividend?
The last dividend was paid out on 6/30/2024.
What was the dividend of MaxCyte in the year 2023?
In the year 2023, MaxCyte distributed 0 USD as dividends.
In which currency does MaxCyte pay out the dividend?
The dividends of MaxCyte are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von MaxCyte
Our stock analysis for MaxCyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MaxCyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.